Global Chronic Kidney Disease Market Size by Diagnosis (Blood Tests, Urine Tests, Imaging Tests), by Treatment (ACE Inhibitors, Diuretics, Dialysis), & Region - Key Manufacturers, Analysis, Growth Trends, and Forecast till 2026

  • Category : Healthcare and Pharma
  • |
  • ID : 1332038
  • |
  • Date : October 2019
  • |
  • No of Pages: 121
  • |
  • Publisher : Intellectual Research Partners

Chronic kidney disease is also known as chronic kidney failure characterized by gradual loss of kidney function. There are different types of medications available in market. Medicines cannot reverse CKD, however they are used to treat complications and to slow further kidney damage.

The global chronic kidney disease market was estimated to be valued at USD XX million in 2018 and is projected to reach USD XX million by 2026, at a CAGR of XX% during 2019 to 2026. The major factors for the growth of the chronic kidney disease market include the increasing incidence of cardiovascular disorders and diabetes which leads to chronic kidney diseases, technological advancements in the diagnostic tests for kidney diseases, and rising need for early detection. However, poor patient compliance in some countries and preferable use of generic drugs are the major challenge which may hinder the growth of the global market.

The global chronic kidney disease market is primarily segmented based on different diagnosis, treatment, and regions. On the basis of diagnosis, the market is divided into blood tests, urine, tests, imaging tests, and others. The application covered in the study include ACE inhibitors, angiotensin-II receptor blockers, diuretics, dialysis, and other treatments. Region wise, it is analyzed across North America, Europe, Asia-Pacific, South America, and MEA.

On the basis of diagnosis, the market is split into:
* Blood Tests
* Urine Tests
* Imaging Tests
* Other Tests

On the basis of treatment, the market is split into:
* ACE Inhibitors
* Angiotensin-II Receptor Blockers
* Diuretics
* Dialysis
* Other Treatments

Moreover, the market is classified based on regions and countries as follows:
* North America- U.S., Canada
* Europe- U.K., France, Germany, Italy and Rest of Europe
* Asia-Pacific- China, Japan, India and Rest of Asia Pacific
* South America- Brazil, Mexico and Rest of South America
* Middle East & Africa- South Africa, Saudi Arabia and Rest of Middle East & Africa

Key Market Players:
The key players profiled in the market include:
* Amgen Inc.
* Bristol-Myers Squibb Company
* Fresenius Medical Care AG & amp; Co. KGaA
* Keryx Biopharmaceuticals, Inc.
* Novartis AG
* Sanofi S. A.
* Abbott Laboratories
* Teva Pharmaceutical Industries Ltd
* AstraZeneca
* GlaxoSmithKline PLC

These enterprises are focusing on growth strategies, such as new product launches, expansions, acquisitions, and agreements & partnerships to expand their operations across the globe.

Key Benefits of the Report:
* Global, regional, country, diagnosis, and treatment market size and their forecast from 2015-2026
* Identification and detailed analysis on key market dynamics, such as, drivers, restraints, opportunities, and challenges influencing growth of the market
* Detailed analysis on industry outlook with market specific PESTLE, and supply chain to better understand the market and build expansion strategies
* Identification of key market players and comprehensively analyze their market share and core competencies, detailed financial positions, key products, and unique selling points
* Analysis on key players’ strategic initiatives and competitive developments, such as joint ventures, mergers, and new product launches in the market
* Expert interviews and their insights on market shift, current and future outlook, and factors impacting vendors’ short term and long term strategies
* Detailed insights on emerging regions, diagnosis, and treatment with qualitative and quantitative information and facts

Target Audience:
* Chronic Kidney Disease Drug Manufacturers
* Traders, Importers, and Exporters
* Raw Material Suppliers and Distributors
* Research and Consulting Firms
* Government and Research Organizations
* Associations and Industry Bodies

Research Methodology:
The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective, such as, analyst reports of investment banks. The secondary research is the primary base of our study wherein we conducted extensive data mining, referring to verified data sources, such as, white papers, government and regulatory published articles, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factors, recent investments, market dynamics including technical growth scenario, consumer behavior, and end use trends and dynamics, and production capacity were taken into consideration. Different weightages have been assigned to these parameters and quantified their market impacts using the weighted average analysis to derive the market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with the Key Industry Participants (KIPs), which typically include:
* Manufacturers
* Suppliers
* Distributors
* Government Body & Associations
* Research Institutes

TABLE OF CONTENTS

1. Introduction

2. Research Methodology

3. Executive Summary

4. Global Chronic Kidney Disease Market Overview
4.1. Market Segmentation & Scope
4.2. Market Trends
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Supply Chain Analysis
4.3. Global Chronic Kidney Disease Market - Porter\'s Five Forces Analysis
4.4. Global Chronic Kidney Disease Market - PESTEL Analysis

5. Global Chronic Kidney Disease Market, by Diagnosis
5.1. Global Chronic Kidney Disease Market, Size and Forecast, 2015-2026
5.2. Global Chronic Kidney Disease Market, by Blood Tests, 2015-2026
5.2.1. Key driving factors, trends and opportunities
5.2.2. Market size and forecast, 2015-2026
5.3. Global Chronic Kidney Disease Market, by Urine Tests, 2015-2026
5.3.1. Key driving factors, trends and opportunities
5.3.2. Market size and forecast, 2015-2026
5.4. Global Chronic Kidney Disease Market, by Imaging Tests, 2015-2026
5.4.1. Key driving factors, trends and opportunities
5.4.2. Market size and forecast, 2015-2026
5.5. Global Chronic Kidney Disease Market, by Other Tests, 2015-2026
5.5.1. Key driving factors, trends and opportunities
5.5.2. Market size and forecast, 2015-2026

6. Global Chronic Kidney Disease Market, by Treatment
6.1. Global Chronic Kidney Disease Market, Size and Forecast, 2015-2026
6.2. Global Chronic Kidney Disease Market, by ACE Inhibitors, 2015-2026
6.2.1. Key driving factors, trends and opportunities
6.2.2. Market size and forecast, 2015-2026
6.3. Global Chronic Kidney Disease Market, by Angiotensin-II Receptor Blockers, 2015-2026
6.3.1. Key driving factors, trends and opportunities
6.3.2. Market size and forecast, 2015-2026
6.4. Global Chronic Kidney Disease Market, by Diuretics, 2015-2026
6.4.1. Key driving factors, trends and opportunities
6.4.2. Market size and forecast, 2015-2026
6.5. Global Chronic Kidney Disease Market, by Dialysis, 2015-2026
6.5.1. Key driving factors, trends and opportunities
6.5.2. Market size and forecast, 2015-2026
6.6. Global Chronic Kidney Disease Market, by Other Treatments, 2015-2026
6.6.1. Key driving factors, trends and opportunities
6.6.2. Market size and forecast, 2015-2026

7. Global Chronic Kidney Disease Market, by Region
7.1. Chronic Kidney Disease Market Regional Analysis, 2015-2026
7.2. Global Chronic Kidney Disease Market Revenue (USD Million) by Region, 2015-2026
7.3. North America Chronic Kidney Disease Market, 2015-2026
7.3.1. North America Chronic Kidney Disease Market Size and Forecast, 2015-2026
7.3.2. North America Chronic Kidney Disease Market by Country, 2015-2026
7.3.2.1. U.S. Chronic Kidney Disease Market, 2015-2026
7.3.2.2. Canada Chronic Kidney Disease Market, 2015-2026
7.4. Europe Chronic Kidney Disease Market, 2015-2026
7.4.1. Europe Chronic Kidney Disease Market Size and Forecast, 2015-2026
7.4.2. Europe Chronic Kidney Disease Market by Country, 2015-2026
7.4.2.1. Germany Chronic Kidney Disease Market, 2015-2026
7.4.2.2. France Chronic Kidney Disease Market, 2015-2026
7.4.2.3. Italy Chronic Kidney Disease Market, 2015-2026
7.4.2.4. UK Chronic Kidney Disease Market, 2015-2026
7.4.2.5. Spain Chronic Kidney Disease Market, 2015-2026
7.4.2.6. Rest of Europe Chronic Kidney Disease Market, 2015-2026
7.5. Asia Pacific Chronic Kidney Disease Market, 2015-2026
7.5.1. Asia Pacific Chronic Kidney Disease Market Size and Forecast, 2015-2026
7.5.2. Asia Pacific Chronic Kidney Disease Market by Country, 2015-2026
7.5.2.1. Japan Chronic Kidney Disease Market, 2015-2026
7.5.2.2. China Chronic Kidney Disease Market, 2015-2026
7.5.2.3. India Chronic Kidney Disease Market, 2015-2026
7.5.2.4. Rest of Asia Pacific Chronic Kidney Disease Market, 2015-2026
7.6. South America Chronic Kidney Disease Market, 2015-2026
7.6.1. South America Chronic Kidney Disease Market Size and Forecast, 2015-2026
7.6.2. South America Chronic Kidney Disease Market by Country, 2015-2026
7.6.2.1. Mexico Chronic Kidney Disease Market, 2015-2026
7.6.2.2. Brazil Chronic Kidney Disease Market, 2015-2026
7.6.2.3. Rest of South America Chronic Kidney Disease Market, 2015-2026
7.7. Middle East & Africa Chronic Kidney Disease Market, 2015-2026
7.7.1. Middle East & Africa Chronic Kidney Disease Market Size and Forecast, 2015-2026
7.7.2. Middle East & Africa Chronic Kidney Disease Market by Country, 2015-2026
7.7.2.1. Saudi Arabia Chronic Kidney Disease Market, 2015-2026
7.7.2.2. South Africa Chronic Kidney Disease Market, 2015-2026
7.7.2.3. Rest of Middle East & Africa Chronic Kidney Disease Market, 2015-2026

8. Competitive Landscape
8.1. Introduction
8.2. Market Share Analysis/Top Player Positioning, 2018

9. Company Profiles
9.1. Amgen, Inc.
9.1.1. Company Overview
9.1.2. Financial Overview
9.1.3. Product Benchmarking
9.1.4. Key Developments
9.2. Bristol-Myers Squibb Company
9.2.1. Company Overview
9.2.2. Financial Overview
9.2.3. Product Benchmarking
9.2.4. Key Developments
9.3. Fresenius Medical Care AG & amp; Co. KGaA
9.3.1. Company Overview
9.3.2. Financial Overview
9.3.3. Product Benchmarking
9.3.4. Key Developments
9.4. Keryx Biopharmaceuticals, Inc.
9.4.1. Company Overview
9.4.2. Financial Overview
9.4.3. Product Benchmarking
9.4.4. Key Developments
9.5. Novartis AG
9.5.1. Company Overview
9.5.2. Financial Overview
9.5.3. Product Benchmarking
9.5.4. Key Developments
9.6. Sanofi S. A.
9.6.1. Company Overview
9.6.2. Financial Overview
9.6.3. Product Benchmarking
9.6.4. Key Developments
9.7. Abbott Laboratories
9.7.1. Company Overview
9.7.2. Financial Overview
9.7.3. Product Benchmarking
9.7.4. Key Developments
9.8. Teva Pharmaceutical Industries Ltd.
9.8.1. Company Overview
9.8.2. Financial Overview
9.8.3. Product Benchmarking
9.8.4. Key Developments
9.9. AstraZeneca
9.9.1. Company Overview
9.9.2. Financial Overview
9.9.3. Product Benchmarking
9.9.4. Key Developments
9.10. GlaxoSmithKline PLC
9.10.1. Company Overview
9.10.2. Financial Overview
9.10.3. Product Benchmarking
9.10.4. Key Developments

10. Key Insights

Content are not available

Choose License Type